Company intelligence / Profile preview

CYTENA

Freiburg, Baden-Württemberg, Germanycytena.com ↗

Ownership: Private
Employees: ~75
Development stage: Commercial

Overview

CYTENA develops and commercializes advanced laboratory instruments focused on automated single-cell dispensing, clonal cell line generation with documented proof of clonality (>99.99%), high-throughput microbiome analysis, assay automation, and live-cell analysis. Their technologies are widely used in biopharmaceutical R&D workflows including monoclonal antibody production and single-cell omics.

The company does not have a therapeutic pipeline but enables the creation of stable producer cell lines critical to biologic drug development.

No clinical results as they do not develop drugs directly.

Acquired by BICO in 2019.

Therapeutic areas: Other
Modalities: DeviceBiologicCell therapyRecombinant protein
Industry: Drug Discovery Services

Partnerships

Not specifically listed; collaborates broadly with pharma/biotech companies using their instruments.

Beyond the preview

Go deeper on CYTENA.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CYTENA.

Explore the full profile